The plasminogen activation system in tumour invasion and metastasis

Pathology Research and Practice

Volumn 192, Issue 7, 1996, Pages 718-733

  De Vries, T J ^a   Van Muijen, G N P ^a   Ruiter, D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Histochemistry; Plasminogen activator; Prognostic factor; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE;

ANGIOGENESIS; CANCER INVASION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR PROBE; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH; ULCER;

EID: 0029747289     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(96)80094-X     Document Type: Article

References (242)

1. Andreasen PA, Nielsen LS, Kristensen P, Grendahl-Hansen J, Skriver L, Danø (1986) Plasminogen activator inhibitor form human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 261: 7644-7651
2. Andreasen PA, Sottrup-Jensen L, Kjøller L, Nykjær A, Moestrup SK, Petersen CM, Gliemann J (1994) Receptor mediated endocytosis of plasminogen activator/inhibitor complexes. FEBS Letters 338: 239-245
3. 2-macroglobulin. J. Cell Biol 110: 1041-1048
4. Åstedt B, Lecander I, Brodin T, Lundblad A, Löw K (1985) Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 53: 122-125
5. Bacharach E, Itin A, Keshet E (1992) In vivo patterns of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA 89: 10686-10690
6. Bastholm L, Nielsen MH, De Mey J, Danø K, Brünner N, Heyer-Hansen G, Rønne E, Elling F (1994) Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotechnic Histochem 69: 61-67
7. Behrendt N, Rønne E, Danø K (1993) Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 268: 5985-5989
8. Belin D, Wohlwend A, Schleuning WD, Kruithof EKO, Vassalli J-D (1989) Facultative polypeptide translocation allows a single messenger RNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor-2. Embo J 8: 3287-3294
9. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS (1993) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866
10. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603
11. Blasi F (1988) Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73-84
12. Blasi F (1993) Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 15: 105-111
13. Bohuslav J, Horejsí V, Hansmann C, Stöckl, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H (1995) Urokinase plasminogen activator receptor, β2-integrins, and src-kinases within a single receptor complex of human monocytes. J Exp Med 181: 1381-1390
14. Borregaard N, Christensen L, Bjerrum OW, Birgens HS, Clemmensen I (1990) Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contain tetranectin and latent alkaline phosphatase. J Clin Invest 85: 408-416
15. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Ogtobine J (1994) Prognostic value of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast cancer. Br J Cancer 69: 398-405
16. Boyd D, Florent G, Kim P, Brattain M (1988) Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112-3116
17. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG (1992) Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res 52: 3043-3047
18. 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 89: 7427-7431
19. Bu G, Maksymovitch EA, Geuze H, Schwartz AL (1994) Subcellular localization and endocytic function of low density Hpoprotein receptor-related protein in human glioblastoma cells. J Biol Chem 269: 29874-29882
20. Bu G, Geuze HJ, Strous GJ, Schwartz AL (1995) 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 14: 2269-2280
21. Burtin P, Chavanel G, Andre J (1985) The plasmin system in human colonic tumors: an immunofluorescence study. Int J Cancer 35: 307-314
22. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126: 259-270
23. Caccamo DV, Keohane ME, McKeever PE (1994) Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Modern Pathol 7: 99-104
24. Casslén B, Astedt B (1992) The plasminogen activation system in ovarian carcinomas. Fibrinolysis 6 (suppl) 4: 65-69
25. Casslén B, Bossmar T, Lecander I, Åstedt (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer 30A: 1302-1309
26. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M, Mulligan RC, Collen D (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92: 2756-2760
27. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Van den Oord JJ, Collen D, Mulligan RC (1994) Physiological consequence of loss of plasminogen activator gene function in mice. Nature 368: 419-424
28. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M (1994) Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454
29. Cavallaro U, Del Vecchio A, Lappi DA, Soria MR (1993) A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem 268: 23186-23190
30. Chambers SK, Gertz RE, Ivins CM, Kacinski BA (1995) The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75: 1627-1633
31. Christensen L, Clemmensen I (1991) Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 95: 427-433
32. Clemmensen I, Petersen LC, Kluft C (1986) Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 156: 327-333
33. Clemmensen I, Lund LF, Christensen L, Andreasen P (1991) A tetranectin-related protein is produced and deposited in extracellular matrix by human fibroblasts. Eur J Biochem 195: 735-741
34. 2-macroglobulin receptor. J Biol Chem 269: 17886-17892
35. 2-macroglobulin in human U937 cells. FEBS Letters 358: 73-78
36. Correc P, Fondanèche M-C, Bracke M, Burtin P (1990) The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines. Int J Cancer 46: 745-750
37. Coucke P, Baramova E, Leprince P, De Pauw-Gillet M-C, Foidart J-M, Bassleer R (1994) Metalloproteinases and serine proteases activities in mixed spheroids of mouse B16 melanoma cells and fibroblascs. Int J Oncology 5: 1125-1130
38. Crowley GW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025
39. Cubeilis MV, Wun TC, Blasi F (1990) Receptormediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085
40. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activation, tissue degradation and cancer. Adv Cancer Res 44: 139-266
41. Danø K, Behrendt N, Brünner, N, Ellis V, Ploug M, Pyke C (1994) The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8 (suppl) 1: 189-203
42. Delbaldo C, Masouye I, Saurat J-H, Vassalli J-D, Sappino A-P (1994) Plasminogen activation in melanocytic neoplasia. Cancer Res 54: 4547-4552
43. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiato G, Esposito G, Salvatore M (1993) Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206
44. De Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GNP (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70-81
45. De Vries TJ, Mooy CM, Van Balken MR, Luyten GPM, Quax PHA, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GNP (1995) Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 175: 59-67
46. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennely JJ, Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62: 531-533
47. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ, Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
48. Duffy MJ (1993) Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7: 295-302
49. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ (1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
50. Ellis V, Behrendt N, Danø K (1991) Plasminogen activation by receptor-bound urokinase - a kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752-12758
51. Ellis V, Danø K (1993) Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J 298: 505-510
52. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792
53. Fazioli F, Blasi F (1994) Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? TiPS 15: 25-29
54. Feinberg RE, Kao L-C, Haimowitz JE, Queenan JT, Wun T-C, Strauss JF, Kliman HJ (1989) Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. Lab Invest 61: 20-26
55. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA (1993) Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 82: 2433-2441
56. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eight G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138
57. Foekens JA, Schmitt M, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
58. Foekens JA, Buessecker F, Peters HA, Krainick U, Van Putten WLJ, Look MP, Klijn JGM, Kramer MD (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427
59. Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen H, Klijn JGM (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
60. Frixen UH, Nagamime Y (1993) Stimulation of urokinase-type plasminogen activator expression by blockage of E-Cadherin-dependent cell-cell adhesion. Cancer Res 53: 3618-3623
61. Ganesh S, Sier CFM, Griffioun G, Vloedgraven HJM, de Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBH, Verspaget HW (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071
62. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBHW, Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402
63. Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yacoub IZ (1995) Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 146: 1150-1160
64. 2-macroglobulin receptor/LRP, a growth regulatory axis. Ann. NY Acad. Sci. 737: 273-290
65. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S (1994) High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 91: 7129-7133
66. Gris J-C, Schved J-F, Marty-Double CM, Mauboussin JM, Balmes P (1993) Immunohistochemical study of tumor cell-associated plasminogen activators and plasaminogen activator inhibitors in lung carcinomas. Chest 104: 8-13
67. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K (1988) Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization. J Invest Derm 90: 790-795
68. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K (1991) Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111-117
69. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft (1993) High levels of urokmase-rype plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
70. Hagège J, Peraldi MN, Rondeau E, Adida C, Delarue F, Medcalf R, Schleuning WD, Sraer JD (1992) Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells. Am J Path 141: 117-128
71. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A (1992) The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873
72. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A (1994) The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151: 16-20
73. Hearing VJ, Law LW, Corti A, Appella E, Blasi F (1988) Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270-1278
74. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch K-W, Loehrs U, Schildberg FW (1995) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol (in press)
75. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF (1992) Transcriprional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489-2496
76. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK (1988) Surface localization and high affinity for calcium of a 500 kDa liver membrane protein closely related to the LDL-receptor suggests a physiological role as lipoprotein receptor. EMBO J. 7: 4119-4127
77. 2-macroglobulin receptor. J Biol Chem 266: 21232-21238
78. Herz J, Clouthier DE, Hammer RE (1992) LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71: 411-421
79. Hofmann GE, Glatstein I, Schatz F, Heller D, Dehgdisch L (1994) Immunohistochemical localization of urokinasetype plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol 170: 671-676
80. Høgdall CK, Christensen L, Clemmensen I (1993) The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 72: 2415-2422
81. Hollas W, Blasi F, Boyd D (1991) Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 52: 3690-3695
82. Huarte J, Belin D, Vassalli (1985) Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell 43: 551-558
83. Huarte J, Belin D, Bosco D, Sappino A-P, Vassalli J-D (1987) Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface. J Cell Biol 104: 1281-1289
84. Huber K, Kirchheimer JC, Ermler D, Bell C, Binder BR (1992) Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with α-Fetoprotein. Cancer Res 52: 1717-1720
85. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR (1993) Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53: 1788-1793
86. ladonato SP, Bu G, Maksymovitch EA, Schwartz AL (1993) Interaction of a 39 kDa protein with the low-density-hpoprotein-receptor-related protein (LRP) on rat hepatoma cells. Biochem J 298: 867-875
87. Jänicke F, Schmitt M, Harter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
88. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H (1993) Urokinase (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in nodenegative breast cancer. Breast Cancer Res Treatment 24: 195-208
89. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530
90. Jankun J, Merrick HW, Gollblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53: 135-144
91. Jensen BA, Clemmensen I (1988) Plasma tetranectin is reduced in cancer and related metastases. Cancer 62: 3222-3227
92. 2-macroglobulin-proteinase complex binding: a common but not exclusive characteristic of malignant cells. In vivo 3: 7-9
93. Jensen PJ, Wheelock MJ (1992) Regulation of urokinase plasminogen activator localization in keratinocytes by calcium ion and E-Cadherin. Exp Cell Res 202: 190-198
94. 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Oncology Res 6: 65-372
95. Karikó K, Kuo A, Boyd D, Okada S, Cines DB, Barnathan ES (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cells line. Cancer Res 53: 3109-3117
96. Kirchheimer JC, Remold HG (1989) Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol 343: 2634-2639
97. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H (1991) Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-u-PA). J Biol Chem 266: 5147-5152
98. Kobayashi H, Ohi H, Shinohara H, Sugimura M, Fujii T, Terao T, Schmitt M, Goertzki L, Chucholowski N, Jänicke F, Graeff H (1993) Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 67: 537-544
99. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T (1994) Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 57: 727-737
100. Kobayashi H, Fujishiro S, Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548
101. Kohga S, Harvey SR, Weaver RM, Markus G (1985) Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787-1796
102. Kohga S, Harvey SR, Suzumiya J, Sumiyoshi A, Markus G (1989) Comparison of the immunohistochemical localisation of urokinase in normal and cancerous human colon tissue. Fibrinolysis 3: 17-22
103. Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55: 1856-1862
104. Kono S, Rao JS, Bruner JM, Sawaya R (1994) Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 53: 256-262
105. Kook YH, Adamski J, Zelent A, Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991
106. Kost C, Stüber W, Ehrlich HJ, Pannekoek H, Preissner KT (1992) Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin-binding region reveals a novel virronectin-dependent feedback mechanism for the cantrol of plasmin formation. J Biol Chem 267: 12098-12105
107. Krieger M, Herz J (1994) Structures and functions of multiligand receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63: 601-637
108. Kruithof EKO (1988) Plasminogen activator inhibitors - a review. Enzyme 40: 113-121
109. Kwaan HC, Radosevich JA, Xu CG, Lastre C (1988) Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma. Tumor Biol 9: 301-306
110. Landau BJ, Kwaan HC, Verrusio EN, Brem SS (1994) Elevated levels of urokinase-rype plasminogen activator and plasminogen activator inhibitor-type-1 in malignant human brain tumors. Cancer Res 54: 1105-1108
111. Larsson G, Larsson Å, Åstedt B (1987) Tissue plasminogen activator and urokinase in normal, dyspslastic and cancerous squamous epithelium of the uterine cervix. Thrombosis and Haemostasis 58: 822-826
112. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO (1993) Inhibition of invasion of HT1080 sarcoma cells expression recombinant plasminogen activaror inhibitor 2. Cancer Res 53: 6051-6057
113. Lecander I, Martinson G, Casslen B, Andreasen PA, Åstedt B (1990) Occurence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinomoa. Fibrinolysis 4: 221-224
114. r 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 55: 963-967
115. Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (suppl): 5054-5059
116. Liu G, Shuman MA, Cohen RL (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506
117. 2-macroglobulin receptor/low density lipoprotein receptor-related protein is increased in reactive and neoplastic glial cells, FEBS Letters 338: 301-305
118. 2-macroglobulin/ low density lipoprotein receptor-related protein in photodynamic therapy-resistant mouse tumour cells. Cancer Res 55: 1820-1823
119. Marcel MM, Van Roy FM, Bracke ME (1993) How and when do tumor cells metastasize? Crit Rev in Oncogenesis 4: 559-594
120. Markus G, Cmiolo SM, Kohga S, Madeja JM, Mittelman A (1983) Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 43: 5517-5525
121. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C (1984) Plasminogen activators in human malignant melanoma. J Nat Cancer Inst 72: 1213-1222
122. Matośka J, Wahlström T, Vaheri A, Bízik J, Grófová M (1988) Tumor-associated alpha-2-macroglobulin in human melanomas. Int J Cancer 41: 359-363
123. Meissauer A, Kramer MD, Schirrmacher V, Brunner G (1992) Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res 199: 179-190
124. Mignatti P, Robbins E, Rifkin DB (1986) Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498
125. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Reviews 73(1): 161-195
126. Miles LA, Plow EF (1991) Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2: 61-71
127. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS (1992) Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not in basal cell carcinomas. J Invest Dermatol 89: 351-358
128. 2-macroglobulin receptor on human malignant blood cells. Leukemia Res 16: 227-234
129. 2MR/LRP) cluster workshop report. In: Leukocyte Typing V, Oxford University Press (in press)
130. Mohanam S, Sawaya R, McCutcheort I, Ali-Osman F, Boyd D, Rao JS (1993) Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147
131. Møller LB, Ploug M, Blasi F (1992) Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem 208: 493-500
132. Møller LB, Pöllänen J, Rønne E, Pedersen N, Blasi F (1993) N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 268: 11152-11159
133. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ (1992) Structural basis of latency in plasminogen activator inhibitor-1. Nature 355: 270-273
134. Mueller BM, Yu YB, Laug WE (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92: 205-209
135. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K (1994) Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584
136. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio M-C, Eber M, Methlin G, Chambon P, Basset P (1993) Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53: 165-169
137. Myöhinen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A (1993) Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 41: 1291-1301
138. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1993) Plasminogen activators and their inhibitors in non-small cell lung cancer. Cancer 73: 1398-1405
139. Nakamura M, Konno H, Tanaka T, Maruo Y, Nishino N, Aoki K, Baba S, Sakaguchi S, Takada Y, Takada A (1992) Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res 65: 709-719
140. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder J, Fink U, Siewert JR (1994) Prognostic impact of urokinase-type plaminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
141. Nielsen H, Clemmensen I, Nielsen HJ, Drivsholm A (1990) Decreased tetranectin in multiple myeloma. Am J Hematol 33: 142-144
142. Nielsen H, Clemmensen I, Kharazmi A (1993) Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 37: 39-42
143. Nip J, Rabbani SA, Shibata HR, Brodt P (1995) Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 95: 2096-2103
144. 2-macroglobulin receptor/LDL receptor-related protein binds urokinaseplasmmogen activator inhibitor type-1 complex. J Biol Chem 267: 14543-14546
145. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. J Biol Chem 269: 25668-25676
146. Oka T, Ishida T, Nishino T, Sugimachi K (1991) Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinomas. Cancer Res 51: 3522-3525
147. Okada A, Bellocq J-P, Rouyer N, Chenard M-P, Rio M-C, Chambon P, Basset P (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92: 2730-2734
148. O'Reilly MS, Homgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
149. 2-macroglobulin receptor. Proc Natl Acad Sci USA 89: 7422-7426
150. Ossowski L, Reich E (1983) Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619
151. Ossowski L (1988) Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52: 321-328
152. Ossowski L, Clunie G, Masucci M-T, Blasi F (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112
153. Ossowski L (1992) Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754-6760
154. Parish CR, Jakobsen KB, Coombe DR (1992) A basement-membrane permecability assay which correlates with the metastatic potential of tumour cells. Int J Cancer 52: 378-383
155. Pedersen H, Grøndahl-Hansen, Francis D, Østerlind, Hansen HH, Danø K, Brünner N (1994) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123
156. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K, Grendahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
157. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer Hansen G, Conese M, Giovazzi R, Danø K, Kuhn W, Jänicke F, Blasi F (1993) A
158. Pepper MS, Vassalli J-D, Montesano R, Orci L (1987) Urokinase-type plasminogen activator is induced in migrating cappilary endothelial cells. J Cell Biol 105: 2535-2541
159. Pepper MS, Sappino A-P, Montesano R, Orci L, Vassalli J-D (1992) Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cellular Physiol 153: 129-139
160. Pepper MS, Sappino A-P, Stöcklin R, Montesano R, Orci L, Vassalli J-D (1993) Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122: 673-684
161. Picar O, Rolland Y, Poupon MF (1986) Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res 46: 3290-3294
162. Plessner, T, Ralfkiær E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, Hansen NE, Danø K (1994) Expression of the receptor for urokinase-rype plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 202: 835-841
163. Pöllänen J, Hedman K, Nielsen LS, Danø K, Vaheri A (1988) Ultrastructural localization of plasma membrane-associated urokinase-rype plasminogen activator at focal contacts. J Cell Biol 106: 87-95
164. Pöllänen J, Stephens RW, Vaheri A (1991) Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 50: 273-328
165. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GWH (1992) Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141: 389-396
166. pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EKO, Lijnen HR, Burtin P (1993) The plasminogen activation system in ovarian tumors. Int J Cancer 55: 27-31
167. pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K (1991) Urokinase-type plasminogen is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
168. Pyke C, Kristensen P, Ralfkiær E, Eriksen J, Danø K (1991) The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51: 4067-4071
169. Pyke C, Ralfkiær E, Huhtala P, Hurskainen T, Danø K, Tryggvason K (1992) Localization of messenger RNA for M, 72,000 and 92,000 type PV collagenases in human skin cancers by in situ hybridization. Cancer Res 52: 1336-1341
170. Pyke C, Graem N, Ralfkiær E, Røyer-Hansen G, Brünner N, Danø K (1993) Receptor for urokinase in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915
171. Pyke C, Ralfkiær, Tryggvason K, Danø K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142: 359-365
172. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K (1994) Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24: 131-138
173. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D (1993) Tissue-plasminogen activator is induced as an immediat-early gene during seizure, kindling and long-term potentiation. Nature 361: 453-457
174. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del Rosso M (1995) Reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55: 90-95
175. Quax PHA, Van Leeuwen RTJ, Verspaget HW, Verheijen JH (1990) Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 50: 1488-1494
176. Quax PHA, Van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ, Verheijen JH (1991) Metastatic behaviour of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor and urokinase mediated matrix degradation. J Cell Biol 115: 191-199
177. Quax PHA, Pedersen N, Masucci MT, Weening-Verhoeff EJD, Danø K, Verheijen JH, Blasi F (1991) Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regulation 2: 793-803
178. Quax PHA, Boxman ILA, Van Kesteren CAM, Verheijen JH, Ponec M (1994) Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vivo. Fibrinolysis 8: 221-228
179. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-209
180. Reiter LS, Kruithof EKO, Cajot J-F, Sordat B (1993) The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int J Cancer 53: 444-450
181. Rijken DC, Collen D (1981) Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256: 7035-7041
182. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K (1994) The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Derm 102: 519-522
183. 2-terminal domain of the urokinase receptor. FEBS Letters 288: 233-236
184. Rønne E, Behrendt N, Ploug M, Nielsen HJ, Wöllisch E, Weidle U, Danø K, Høyer-Hansen G (1994) Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 167: 91-101
185. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Danø K, Grøndahl-Hansen J (1995) Urokinase-receptor immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treatment 33: 199-207
186. Saiki I, Murata J, Yoneda J, Kobayashi H, Azuma (1994) Influence of fibroblasts on the invasion and migration of highly or weakly metastatic B16 melanoma cells. Int J Cancer 56: 867-873
187. Saksela O, Wahlström T, Lehtowirta P, Markku S, Vaheri A (1981) Presence of α-2-macroglobulin in normal but not in malignant syncytiotrophoblasts. Cancer Res 41: 2507-2513
188. 2-macroblobulin produced by cultured normal and malignant human cells. Int J Cancer 33: 609-616
189. Saksela O, Wahlström T, Meyer B, Vaheri A (1984) Presence of α-2-macroglobulin in normal but not in malignant cervical epithelium. Cancer Res 44: 2942-2946
190. Salonen E-M, Saksela O, Vartio T, Vaheri A, Nielsen LS, Zeuthern J (1986) Plasminogen and tissue-type plasminogen activator bind to immunobilized fibronectin. J Biol Chem 260: 12302-12307
191. Salonen E-M, Zitting A, Vaheri A (1984) Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett 172: 29-32
192. Sappino A-P, Huarte J, Belin D, Vassalli J-D (1989) Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 109: 2471-2479
193. Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurat J-H, Vassalli J-D (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079
194. Sappino A-P, Huarte J, Vassalli J-D, Belin B (1991) Sites of synthesis of urokinase and tissue-type plasminogen activator in the murine kidney. J Clin Invest 87: 962-970
195. Sappino A-P, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli J-D (1993) Extracellular proteolysis in the adult murine brain. J Clin Invest 92: 679-685
196. Schmitt M, Jänicke F, Graeff H (1990) Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators u-PA and t-PA in human breast cancer. Blood Coagul Fibrinol 1: 695-702
197. Sier CFM, Fellbaum C, Verspaget HW, Schmitt M, Griffioen G, Graeff H, Höfler H, Lamers CBHW (1991) Immunolocalization of urokinase-rype plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 19: 231-237
198. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, de Bruin PAF, Lamers CBHW (1991) Imbalance of plasmmogen activators and their inhibitors in human cololectal neoplasia. Gastroenterology 101: 1522-1528
199. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW (1993) Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 34: 80-85
200. Sier CFM (1993) Regulation of urokinase-type plasminogen activator expression in gastrointestinal neoplasia. Ph.D. thesis, Leiden, The Netherlands
201. Sier CFM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PHA, Verheijen JH, Dooijewaard G, Welvaart K, Van de Velde CJH, Lamers CBH, Verspaget HW (1994) Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastases. Gastroenterology 107: 1449-1456
202. Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69: 81-387
203. Stahl A, Mueller BM (1994) Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54: 3066-3071
204. Stahl A, Mueller BM (1995) The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 129: 335-344
205. Stack MS, Moser TL, Pizzo SV (1992) Binding of human plasminogen to basement membrane (type IV) collagen. Biochem J 284: 103-108
206. Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen EM, Rønne E, Behrendt N, Danø K, Vaheri A (1989) Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surfacebound reactants. J Cell Biol 108: 1987-1995
207. Stoppelli MP, Tachetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F (1986) Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45: 675-684
208. Strickland DK, Ashcom JD, Williams S, Bartey F, Fehre E, McTigre K, Battey JE, Argraves WS (1991) Primary structure of α-macroglobulin receptor-associated protein. J Biol Chem 266: 13364-13369
209. Strickland DK, Kounnas MZ, Williams SE, Argraves WS (1994) LDL receptor-related protein (LRP): a multiligand receptor. Fibrinolysis 8 (suppl. 1): 204-215
210. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S 81992) Plasminogen activation system in human breast cancer. Int J Cancer 50: 345-348
211. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brern S (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660
212. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterology 88: 1928-1933
213. Tan K, Powe DG, Gray T, Turner DR, Hewitt RE (1995) Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis. Int J Cancer 60: 308-314
214. Tanaka H, Mori Y, Ishii H, Akedo H (1988) Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice. Cancer Res 48: 1456-1459
215. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O (1991) Plasminogen activator inhibitor I in carcinoma tissues. Im J Cancer 48: 481-484
216. Tapiovaara H, Alitalo R, Stephens R, Myöhänen, Ruutu T, Vaheri A (1993) Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 82: 914-919
217. Tapiovaara H (1994) Plasminogen activation in leukemia. Ph.D. thesis, Helsinki, Finland
218. Towle MJ, Lee A, Maduakor EC, Schwartz E, Bridges AJ, Littlefield BA (1993) Inhibition of urokinase by 4-substituted benzo(b)thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53: 2553-2559
219. Tryggvason K, Höyhtya M, Salo T (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Bioch Bioph Acta 907: 191-217
220. 2-macroglobulin receptor in human fibroblasts, absennt in tumor-derived cell lines. J Biol Chem 254: 515-5160
221. 2-macroglobulin receptor lipoprotein receptor-related protein. Genomics 24: 78-89
222. r 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92
223. Verspaget HW, Clemmensen I, Ganesh S, Christensen L, Sier CFM, Griffioen G, Lamers CBHW (1994) Tetranectin expression in human colonic neoplasia. Histopathology 25: 463-467
224. Waltz DA, Chapman HA (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750
225. Wang H, Skibber J, Juarez J, Boyd D (1994) Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 58: 650-657
226. Warshawsky I, Bu G, Schwartz AL (1995) Sites within the 39-kDa protein important for regulating ligand binding to the low-density lipoprotein receptor-related protein. Biochemistry 34: 3404-3415
227. Webb G, Baker MS, Nicholl J, Wang Y, Woodrow G, Kruithof E, Doe WF (1994) Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colerectal cancer. J Gastroenterol Hepatol 9: 340-343
228. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388
229. Wewer U, Albrechtsen R (1992) Tetranectin, a plasminogen kringle 4-binding protein. Cloning and gene expression pattern in human colon cancer Lab Invest 67: 253-262
230. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H (1994) Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (u-PA). FEBS Letters 337: 131-134
231. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J (1992) Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 267: 26172-26180
232. Willnow TE, Armstrong SA, Hammer RE, Herz J (1995) Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci 92: 4537-4541
233. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq J-E, Chambon P, Basset P (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90: 1843-1847
234. Yamamoto M, Sawaya R, Mohanam S, Luskutoff DJ, Bruner JM, Rao VH, Oka K, Tomonaga M, Nicolson GL, Rao JS (1994) Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 54: 3329-3332
235. Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS (1994) Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 54: 3656-3661
236. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, Rao JS (1994) Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54: 5016-5020
237. Yamashita J, Ogawa M, Inada S, Yamashita S, Nakashima T, Saishoji T, Nomura K (1993) Breast cancer prognosis is poor when total plasminogen activator activity is low. Br J Cancer 67: 374-378
238. Yamashita J, Ogawa M, Yamashita S, Nakashima Y, Saishoji T, Nomura K, Inada K, Kawano I (1993) Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68: 524-529
239. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS (1994) Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170: 1285-1296
240. Yu H, Schultz RM (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623-7633
241. Zhang S, Laurent M, Lopez-Alemany R, Mazar A, Henkin J, Rønne E, Burtin P (1993) Comparative localization of receptors for plasmin and for urokinase on MCF7 cells. Exp Cell Res 207: 290-299
242. 2 macroglobulin receptor and its receptor-associated protein in late stages of cutaneus melanocytic tumor progression. Cancer Res 56: 1432-1439